CMND vs. ASLN, FWBI, TRVN, LGVN, SHPH, PTIX, PULM, TENX, AIMD, and KTTA
Should you be buying Clearmind Medicine stock or one of its competitors? The main competitors of Clearmind Medicine include ASLAN Pharmaceuticals (ASLN), First Wave BioPharma (FWBI), Trevena (TRVN), Longeveron (LGVN), Shuttle Pharmaceuticals (SHPH), Protagenic Therapeutics (PTIX), Pulmatrix (PULM), Tenax Therapeutics (TENX), Ainos (AIMD), and Pasithea Therapeutics (KTTA). These companies are all part of the "pharmaceutical preparations" industry.
ASLAN Pharmaceuticals (NASDAQ:ASLN) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.
ASLAN Pharmaceuticals presently has a consensus price target of $11.33, indicating a potential upside of 2,543.66%. Given Clearmind Medicine's higher probable upside, analysts plainly believe ASLAN Pharmaceuticals is more favorable than Clearmind Medicine.
In the previous week, ASLAN Pharmaceuticals had 1 more articles in the media than Clearmind Medicine. MarketBeat recorded 3 mentions for ASLAN Pharmaceuticals and 2 mentions for Clearmind Medicine. Clearmind Medicine's average media sentiment score of 0.88 beat ASLAN Pharmaceuticals' score of 0.56 indicating that ASLAN Pharmaceuticals is being referred to more favorably in the media.
ASLAN Pharmaceuticals received 200 more outperform votes than Clearmind Medicine when rated by MarketBeat users.
58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
ASLAN Pharmaceuticals' return on equity of -265.38% beat Clearmind Medicine's return on equity.
Clearmind Medicine has lower revenue, but higher earnings than ASLAN Pharmaceuticals.
ASLAN Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
Summary
ASLAN Pharmaceuticals beats Clearmind Medicine on 9 of the 12 factors compared between the two stocks.
Get Clearmind Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Clearmind Medicine Competitors List
Related Companies and Tools
